Myopathic Alterations in Extraocular Muscle of Rats Subchronically Fed Pyridostigmine Bromide

Abstract

To determine if alterations in extraocular muscle morphology occur after subchronic oral administration of pyridostigmine bromide, rats were continuously fed 90 mg/kg in meal and examined at 1,2, 4, 7, and 15 days. Within the first day, blood acetylcholinesterase activity was reduced by 87% and remained inhibited by 74-91% during the study. Light microscopy demonstrated that by day 1 approximately 3% of the extraocular myofibers were shrunken and invaded by inflammatory cells. The most severe degenerative changes consisting of vacuoles and inflammatory cell infiltration occurred at day 1 with progressively less severe changes at days 2 and 4. At days 7 and 15,1.3-4.5% of the myofibers still exhibited damage. Ultrastructurally, all presynaptic areas were normal but the postsynaptic areas of affected myofibers at days 1,2, and 4 showed myofilament and Z-band dissolution, mitochondrial inclusions, subneural fold and T-tubule/sarcoplasmic reticulum vacuolization and subneural fold depth reduction. By days 7 and 15, these changes were diminished in some cases and in others alterations appeared similar to day 1. We conclude that subchronic feeding of pyridostigmine bromide induces myopathic rather than neurogenic changes in rat extraocular muscle and that the myopathy is different in these muscles than in the diaphragm from the same rats.

Keywords

Neuromuscular junction acetylcholinesterase anticholinesterases Z-bands calcium degeneration regeneration

References

1. Ariens AT , Meeter E , Wolthius OL , and Van Ben-them RMJ (1969). Reversible necrosis at the end-plate region in striated muscles of the rat poisoned with colinesterase inhibitors. Experientia 25: 57–59.

2. Bach Y , Rita P , and Ito F (1966). In vivo studies on fast and slow muscle fibers in cat extraocular muscles. J. Gen. Physiol. 49: 1177–1198.

3. Bowman PD , Schuschereba ST , Johnson TW , Woo FJ , McKinney L , Wheeler CR , Frost DF , and Korte DW (1989). Myopathic changes in diaphragm of rats fed pyridostigmine bromide subchroriically. Fun-dam. Appl. Toxicol. 13: 110–117.

4. Chan PK , O'Hara GP , and Hayes AW (1982). Principals and methods for acute and subchronic toxicity. In: Principals and Methods of Toxicology, AW Hayes (ed). Raven Press, New York, pp. 1–51.

5. Engel AG , Tsujihata MT , Lindstrom JM , and Lennon VA (1976). The motor end plate in myasthenia gravis and in experimental autoimmune myasthenia gravis. A quantitative ultrastructural study. Annals of N. Y. Acad, of Sciences. Myasthenia gravis. 274: 60–78.

6. Fenichel GM , Kibler WB , Olson WH , and Dettbarn WD (1972). Chronic inhibition of cholinesterase as a cause of myopathy. Neurology 22: 1026–1033.

7. Gebbers J-O , Lotscher M , Kobel W , Portmann R , and Laissue J-A (1986). Acute toxicity of pyridostigmine in rats: Histological findings. Arch. Toxicol. 58: 271–275.

8. Hudson CS , Foster RE , and Kahng MW (1986). Neuromuscular toxicity of pyridostigmine bromide in the diaphragm, extensor digitorum longus and soleus muscles of the rat. Fundam. Appl. Toxicol. 5: S260–S269.

9. Humphrey CD and Pittman FE (1974). A simple methylene blue-azure-II basic fuchsin stain for ep-oxy-embedded tissue sections. Stain Technol. 49: 9–14.

10.

10. Jackson MJ , Jones DA , and Edwards HT (1984). Experimental skeletal muscle damage: The nature of the calcium-activated degenerative processes. Eur. J. Clin. Invest. 14: 369–374.

11.

11. Kamovsky MJ (1965). A formaldehyde-glutaralde-hyde fixative of high osmolality for use in electron microscopy. J. Cell Biol. 27; 137A–138A.

12.

12. Kawabuchi M , Osame M , Watanabe S , Igata A , and Kanaseki R (1976). Myopathic changes at the end-plate induced by neostigmine methylsulfate. Experientia 32: 623–625.

13.

13. Leadbeater L , Inns RH , and Rylands JM (1985). Treatment for poisoning by Soman. Fundam. Appl. Toxicol. 5: S225–S231.

14.

14. Leonard JP and Salpeter MM (1979). Agonist-induced myopathy at the neuromuscular junction is mediated by calcium. J. Cell Biol. 82: 811–819.

15.

15. Mastaglia FL and Hudgson P (1981). Ultrastructural studies of diseased muscle. In: Disorders of Voluntary Muscle, 4th ed., J Walton (ed). Churchill Livingstone, New York, pp. 296–356.

16.

16. Mayr R (1971). Structure and distribution of fibre types in the external eye muscles of the rat. Tissue Cell. 3: 433–462.

17.

17. Meshul CK , Boyne AF , Deshpande SS , and Albuquerque EX (1985). Comparison of the ultrastructural myopathy induced by anticholinesterase agents at the end plates of rat soleus and extensor muscles. Exp. Neurol. 89: 96–114.

18.

18. Salpeter MM , Leonard JP , and Kasprzak H (1982). Agonist-induced postsynaptic myopathy. Neurosci. Comment. 1: 73–83.

19.

19. Salpeter MM , Rodgers AW , Kasprzak H , and Mc-Henry FA (1978). Acetylcholinesterase in the fast extraocular muscle of the mouse by light and electron microscope autoradiography. J. Cell Biol 78: 274–285.

20.

20. Siakotos AN , Filbert M , and Hester R (1969). A specific radioisotopic assay for acetylcholinesterase and pseudocholinesterase in brain and plasma. Biochem. Med. 3: 1–12.

21.

21. Taylor P (1985). Anticholinesterase agents. In: The Pharmacological Basis of Therapeutics, 7th ed., AG Gilman , LS Goodman , TW Rall , and F Murad (eds). Macmillan Pub. Co., New York, p. 123.